pharmaspecialist
14 Sep 2016
Re: Good Results / bright future Yes the results look OK to me, with some organic growth apparent in addition to the debt-financed growth. As I suspected, the culture at Sinclair Healthcare is different to that at Alliance as evidenced by the statement "we are working hard to implement standard ways of working and to develop a common culture" so it is important that this can be pursued without causing problems. As a shareholder, I would happy for the next couple of years to be a "steady as she goes" period whilst these issues are resolved and factors constraining cash generation drop away.
winningstreak
14 Sep 2016
Good Results / bright future H1 Results look good to me. I topped up. In my view, the future for APH looks sound, safe and bright. Expanding sales in the virtual recession-proof health market, what can be a surer & better bet than that? I hold for the longterm, fully expecting to see the share price to rise steadily as we go along, whilst enjoying a nice wee drip of dividend.ws
mcescher
30 Mar 2016
Solid dividend player with healthy balance sheet but average value, track record, and growth prospects. From this excellent report on Alliance Pharma [link]
winningstreak
29 Mar 2016
Healthcare I favour investing in the healthcare sector, therefore I favour AMS, APH,and today put money on Constellation Healthcare Technologies (CHT)where current share price looks very favourably low IMO.ws
winningstreak
27 Nov 2015
Re: Deal looks good but price looks high Alliance is on a well calculated growth path, for that one can expecta premium in the share price.IMHO,ws
Ripley94
26 Nov 2015
Re: Deal looks good but price looks high One that Tom wiiifrith has been in and out off. Hints its a buy now.
pharmaspecialist
26 Nov 2015
Deal looks good but price looks high So this was the much awaited deal. From a strategic viewpoint the deal with Sinclair Pharma looks good to me but the question is whether the price is too high? The press release suggests that the cost of the deal should start to be covered by returns provided in 2018. However, I wonder how long it will be before the deal becomes truly accretive to earnings. The press release on the Alliance web site refers to it being accretive to earnings for the year ending 31 December 2016, whereas the full press release on Interactive Investor refers to it being accretive to ADJUSTED earnings for this period. There can be a big difference between non-adjusted and and adjusted earnings so I wonder which version is true? I am pretty sure the latter is the correct version as I am sure the company can make it accretive by adjusting the definition of its earnings. Sinclair's CEO & Chairman are from the financial sectors so I can understand why Alliance may have more expertise and motivation to exploit Sinclair's medical products. I can also understand why Sinclair's CEO, Chris Spooner, would regard these medical products as boring in comparison to Sinclair's racier aesthetic products as he was a hedge fund manager and they always like a bit of excitement! In other words I think the medical products may well do better in Alliance's hands and John Dawson has plenty of his own money invested in Alliance so I am sure he would not have entered this deal lightly. On that basis I will remain a shareholder but Alliance has certainly upped the ante. Let's see that debt paid down as soon as possible please. Any other opinions?
Oxtrader
05 Nov 2015
ImmuCyst settlement Surpised the figure was as high as 6 million, haven't checked the figures for what ImmuCyst was doing previously but alas, injected cash flow of almost 6-7% of APH's full year revenues? Impressive 
!
gretel
20 Oct 2015
Bad news re Diclectin I've sold and taken profits. It's been a great run, but APH is now on quite a decent rating and I'm unsure how much if any upside there is.In addition, and on the downside, APH have invested "significant pre-marketing costs" in the launch of Diclectin from next year. However, I've come across this rather controversial news from Canada, where Diclectin is charged with being no more and possibly less efficacious than other products - there's lots of other coverage on the web:[link] luck all.
Oxtrader
13 Sep 2015
Re: Silly article from Motley Fool today Hi pharmaspecialist - I agree! However I bet Glaxo would love to be Alliance's shoes without having the heavy burden of expectation! (Also debt ratios I must add.. )
pharmaspecialist
10 Sep 2015
Silly article from Motley Fool today I really don't understand the value of today's Motley Fool article comparing Alliance Pharma with Glaxo SmithKline and Genus. The companies are completely different businesses with completely different strategies and Genus works in a completely different sector!
pharmaspecialist
10 Sep 2015
Re: Today's Results Yes, I would agree with you Oxtrader. Alliance is doing OK but nothing spectacular. Its net margins are good but ROCE is nothing special and the results show little bottom line growth. I like the increasing focus on consumer healthcare as this involves brands which should help margins and provide products which last for ever. Comments from management in the results confirm my impression that a major deal is in the works and I think this expectation has been driving the share price.
Oxtrader
09 Sep 2015
Today's Results These results had a bit too much 'build up'. Yes Alliance Pharma are progressing, but not by standards that doubles share prices.Nevertheless, in it's 10 year history, Alliance Pharma appears to be on a breakout, sales increasing and it's built a really solid portfolio. I'll be holding for a while to come.
pharmaspecialist
13 Aug 2015
Possible licensing deal? In my earlier post I suggested that the recent steady upward progression of the share price might indicate that a major deal is in the works. If I could extend my speculation further (and it is pure speculation) I notice that the competition watchdog has demanded that Reckitt Benckiser initially (for 8 years) license out the K-Y lubricant brand it has purchased from Johnson & Johnson and I wonder if there is any chance that Alliance could licence this, having already done an earlier deal on other products with Reckitt Benckiser in 2009. From Reckitt's viewpoint this might be considered a good deal as Alliance might not have the marketing clout to use this as a base to develop a competing lubricant n the long term, but for this reason, such a deal may not satisfy the competition watchdog - just a thought.
gretel
07 Aug 2015
Hardman & Co update Hardman have just released their monthly research summary for August. There's a brief summary of APH's trading update - nothing new, but the inbvestment summary is a useful précis:"Investment summary and share performance:The share price has performed very strongly over the past month, rising 36% andunderpinned by above-average trading volumes, as the market reflected on the trading statement and future outlook for growth. Trading on FY15 prospective PE of 16.7x with a 2014-2018 EPS CAGR estimate of 10%, EV/EBITDA of 12.1x with a FCF yield of 6.1%. The dividend yield is 1.9% and 3.1x covered. Interim results are due to be released on 9th September."
